WENTWORTH KORY JAMES 4
4 · Entrada Therapeutics, Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Entrada (TRDA) CFO Kory Wentworth Receives RSUs; Sell-to-Cover $101K
What Happened
CFO Kory Wentworth received two equity awards on March 1, 2026: 44,600 shares (award at $0.00) and 66,600 derivative shares/awards (also $0.00). To cover minimum statutory withholding, the company automatically sold portions of his shares: 2,939 shares on March 2, 2026 (weighted avg price $11.66) for $34,263 and 5,712 shares on March 3, 2026 (weighted avg price $11.76) for $67,153 — about $101,416 total. The sales were mandatory sell-to-cover transactions, not discretionary trades by the reporting person.
Key Details
- Transaction dates: March 1, 2026 (awards); March 2, 2026 and March 3, 2026 (automatic sales). Filing date: March 3, 2026.
- Awarded: 44,600 shares (grant) and 66,600 derivative awards (total 111,200). Both reported at $0.00 acquisition price.
- Sales: 2,939 shares (WAP $11.66; price range reported 11.17–11.91) and 5,712 shares (WAP $11.76; price range reported 11.22–12.095).
- Proceeds: ~$34,263 and ~$67,153 respectively (≈ $101,416 total) used to satisfy tax withholding.
- Shares owned after transaction: not stated in the filing.
- Notable footnotes: F1 describes RSU vesting (25% each March 1, 2027–2030); F2 confirms the sales were mandatory sell-to-cover; F3/F4 note weighted-average pricing ranges; F5 describes a separate option-style vesting schedule for derivative awards.
- Timeliness: Filing appears timely (filed March 3 for March 1–3 transactions); no late-filing flag noted.
Context
This is primarily a grant (award) event with routine, automatic sell-to-cover sales to satisfy tax withholding — a common administrative step that does not necessarily signal personal selling intent. The awards include RSU-style and/or derivative awards with multi-year vesting schedules, meaning the recipient only receives the underlying shares as they vest over 2027–2030.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-01+44,600→ 154,626 total - Tax Payment
Common Stock
[F2][F3]2026-03-02$11.66/sh−2,939$34,263→ 151,687 total - Tax Payment
Common Stock
[F2][F4]2026-03-03$11.76/sh−5,712$67,153→ 145,975 total - Award
Stock Option (Right to Buy)
[F5]2026-03-01+66,600→ 66,600 totalExercise: $11.93Exp: 2036-03-01→ Common Stock (66,600 underlying)
Footnotes (5)
- [F1]Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- [F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.